Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children

References

• HomsyJMooreDBarasaAWereWLikichoCWaiswaBBreastfeeding, Mother-to-Child HIV Transmission, and Mortality Among Infants Born to HIV-Infected Women on Highly Active Antiretroviral Therapy in Rural UgandaJ Acquir Immune Defic Syndr2009 [Sep 30 Epub ahead of print]
   Web of Science ®Google Scholar
• SutcliffeCGvan DijkJHBoltonCPersaudDMossWJEffectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan AfricaLancet Infect Dis20088847748918652994
   PubMed Web of Science ®Google Scholar
• PrendergastAMphatsweWTudor-WilliamsGRakgothoMPillayVThobakgaleCEarly virological suppression with three-class antiretroviral therapy in HIV-infected African infantsAids200822111333134318580613
   PubMed Web of Science ®Google Scholar
• PrendergastATudor-WilliamsGJeenaPBurchettSGoulderPInternational perspectives, progress, and future challenges of paediatric HIV infectionLancet20073709581688017617274
   PubMed Web of Science ®Google Scholar
• DoerholtKDuongTTookeyPButlerKLyallHSharlandMOutcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapyPediatr Infect Dis J200625542042616645506
   PubMed Web of Science ®Google Scholar
• HarwellJIObaroSKAntiretroviral therapy for children: substantial benefit but limited accessJAMA2006296333033116849666
   PubMed Web of Science ®Google Scholar
• VaclavikovaJMachalaLStankovaMLinkaMBruckovaMVandasovaJResponse of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavirJ Clin Virol200533431932316036182
   PubMed Web of Science ®Google Scholar
• The devastating effects of HIV/AIDS on childrenLancet20063689534424
   Web of Science ®Google Scholar
• RamosJBoosted protease inhibitors as a therapeutic option in the treatment of HIV-infected childrenHIV Med200910953654719785664
   PubMed Web of Science ®Google Scholar
• SharlandMBlancheSCastelliGRamosJGibbDMPENTA guidelines for the use of antiretroviral therapy, 2004HIV Med20045 Suppl 2618615239717
   PubMed Web of Science ®Google Scholar
• ShafranSDMashinterLDRobertsSEThe effect of low-dose ritonavir monotherapy on fasting serum lipid concentrationsHIV Med20056642142516268824
   PubMed Web of Science ®Google Scholar
• RudinCBurriMShenYRodeRNadalDLong-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral- experienced HIV-infected childrenPediatr Infect Dis J200827543143718382386
   PubMed Web of Science ®Google Scholar
• Saez-LlorensXViolariADeetzCORodeRAGomezPHandelsmanEForty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenPediatr Infect Dis J200322321622412634581
   PubMed Web of Science ®Google Scholar
• ChandwaniAShuterJLopinavir/ritonavir in the treatment of HIV-1 infection: a reviewTher Clin Risk Manag2008451023103319209283
   PubMedGoogle Scholar
• KleinCEChiuYLAwniWZhuTHeuserRSDoanTThe tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effectJ Acquir Immune Defic Syndr200744440141017224848
   PubMed Web of Science ®Google Scholar
• NewellMLPatelDGoetghebuerTThorneCCD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?J Infect Dis2006193795496216518757
   PubMed Web of Science ®Google Scholar
• VerweelGSaavedra-LozanoJvan RossumAMRamiloOde GrootRInitiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidencePediatr Infect Dis J2006251198799417072119
   PubMed Web of Science ®Google Scholar
• RiordanABugembeTUpdate on antiretroviral therapyArch Dis Child2009941707418838416
   PubMed Web of Science ®Google Scholar
• ViolariACottonMFGibbDMBabikerAGSteynJMadhiSAEarly antiretroviral therapy and mortality among HIV-infected infantsN Engl J Med2008359212233224419020325
   PubMed Web of Science ®Google Scholar
• GoetghebuerTHLe ChenadecEEarly versus deferred highly active antiretroviral therapy in HIV infected infants: a European Collaborative Cohort Study4th Dominique Dormont International Conference: Host-Pathogen Interactions in Chronic InfectionsParis, France13–15 December, 2007
   Google Scholar
• ObimboEMMbori-NgachaDAOchiengJORichardsonBAOtienoPABosireRPredictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African childrenPediatr Infect Dis J200423653654315194835
   PubMed Web of Science ®Google Scholar
• GortmakerSLHughesMCerviaJBradyMJohnsonGMSeageGR3rdEffect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1N Engl J Med2001345211522152811794218
   PubMed Web of Science ®Google Scholar
• LockmanSShapiroRLSmeatonLMWesterCThiorIStevensLResponse to antiretroviral therapy after a single, peripartum dose of nevirapineN Engl J Med2007356213514717215531
   PubMed Web of Science ®Google Scholar
• ChadwickEGCapparelliEVYogevRPintoJARobbinsBRodmanJHPharmacokinetics, safety and efficacy of lopinavir/ ritonavir in infants less than 6 months of age: 24 week resultsAIDS200822224925518097227
   PubMed Web of Science ®Google Scholar
• HirtDUrienSJullienVFirtionGReyEPonsGAge-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 childrenAntimicrob Agents Chemother200650391091616495250
   PubMed Web of Science ®Google Scholar
• KlineMWRuginaSIlieMMatusaRFSchweitzerAMCallesNRLong-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapyPediatrics20071195e1116e112017420261
   PubMed Web of Science ®Google Scholar
• ChadwickEGPintoJYogevRAlveroCGHughesMDPalumboPEarly initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacyPediatr Infect Dis J200928321521919209098
   PubMed Web of Science ®Google Scholar
• VerweelGBurgerDMSheehanNLBergshoeffASWarrisAvan der KnaapLCPlasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and belowAntivir Ther200712445345817668553
   PubMed Web of Science ®Google Scholar
• DelaugerreCFlandrePChaixMLGhosnJRaffiFDellamonicaPProtease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapyAntimicrob Agents Chemother20095372934293919451297
   PubMed Web of Science ®Google Scholar
• MoltoJSantosJRNegredoEMirandaCVidelaSClotetBLopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practiceJ Antimicrob Chemother200760243643917556354
   PubMed Web of Science ®Google Scholar
• PulidoFArribasJRDelgadoRCabreroEGonzalez-GarciaJPerez-EliasMJLopinavir-ritonavir monotherapy versus lopinavir- ritonavir and two nucleosides for maintenance therapy of HIVAIDS2008222F1F918097218
   PubMed Web of Science ®Google Scholar
• DelfraissyJFFlandrePDelaugerreCGhosnJHorbanAGirardPMLopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patientsAIDS200822338539318195565
   PubMed Web of Science ®Google Scholar
• GhosnJFlandrePCohen-CodarIGirardPMChaixMLRaffiFLong-term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trialHIV Med2009 [Aug 13 Epub ahead of print]
   Web of Science ®Google Scholar
• LePrevostMGreenHFlynnJHeadSClapsonMLyallHAdherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected childrenPediatr Infect Dis J200625653353716732152
   PubMed Web of Science ®Google Scholar
• JohnsonMAGatheJCJrPodzamczerDMolinaJMNaylorCTChiuYLA once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenJ Acquir Immune Defic Syndr200643215316016951643
   PubMed Web of Science ®Google Scholar
• AnanworanichJGayet-AgeronARuxrungthamKChetchotisakdPPrasithsirikulWKiertiburanakulSLong-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavirAntivir Ther200813337538018572750
   PubMed Web of Science ®Google Scholar
• EronJJFeinbergJKesslerHAHorowitzHWWittMDCarpioFFOnce-daily versus twice-daily lopinavir/ritonavir in antiretroviralnaive HIV-positive patients: a 48-week randomized clinical trialJ Infect Dis2004189226527214722892
   PubMed Web of Science ®Google Scholar
• MacassaEDelaugerreCTeglasJPJullienVTreluyerJMVeberFChange to a once-daily combination including boosted atazanavir in HIV-1-infected childrenPediatr Infect Dis J200625980981416940839
   PubMed Web of Science ®Google Scholar
• Children. WGoATaMMoH-IGuidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection2232009
   Google Scholar
• WelchSSharlandMLyallEGTudor-WilliamsGNiehuesTWintergerstUPENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infectionHIV Med2009101059161319878352
   PubMed Web of Science ®Google Scholar
• GuptaRKGibbDMPillayDManagement of paediatric HIV-1 resistanceCurr Opin Infect Dis200922325626319405216
   PubMed Web of Science ®Google Scholar
• van der LugtJAutarRSUbolyamSGarciaEFSankoteJAvihingsanonAPharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1- infected adultsJ Antimicrob Chemother20086151145115318285316
   PubMed Web of Science ®Google Scholar
• StebbingJScourfieldAKohGTaylorCTaylorSWilkinsEA multicentre cohort experience with double-boosted protease inhibitorsJ Antimicrob Chemother200964243443519474068
   PubMed Web of Science ®Google Scholar
• LandmanRCapitantCDescampsDChazallonCPeytavinGKatlamaCEfficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 studyJ Antimicrob Chemother200964111812519420019
   PubMed Web of Science ®Google Scholar
• DunningJNelsonMNovel strategies to treat antiretroviral-naive HIV-infected patientsJ Antimicrob Chemother200964467467919643777
   PubMed Web of Science ®Google Scholar
• BoydMMootsikapunPBurgerDChuenyamTUbolyamSMahanontharitAPharmacokinetics of reduced-dose indinavir/ ritonavir 400/100 mg twice daily in HIV-1-infected Thai patientsAntivir Ther200510230130715865224
   PubMed Web of Science ®Google Scholar
• PuthanakitTvan der LugtJBunupuradahTAnanworanichJGorowaraMPhasomsapCPharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected childrenJ Antimicrob Chemother20096451080108619729375
   PubMed Web of Science ®Google Scholar
• LaboratoriesA. Kaletra (lopinavir/ritonavir) tablets and oral solutionPrescribing information http://www.kaletra.comAccessed 1 October 2009
   Google Scholar
• OldfieldVPloskerGLLopinavir/ritonavir: a review of its use in the management of HIV infectionDrugs20066691275129916827606
   PubMed Web of Science ®Google Scholar
• RossoRDi BiagioADentoneCGattinaraGCMartinoAMViganoALopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administrationJ Antimicrob Chemother20065761168117116606636
   PubMed Web of Science ®Google Scholar
• van der LeeMVerweelGde GrootRBurgerDPharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected childrenAntivir Ther200611443944516856617
   PubMed Web of Science ®Google Scholar
• la PorteCvan HeeswijkRMitchellCDZhangGParkerJRongkavilitCPharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected childrenAntivir Ther200914460360619578247
   PubMed Web of Science ®Google Scholar
• van der FlierMVerweelGvan der KnaapLCvan JaarsveldPDriessenGJvan der LeeMPharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once dailyAntivir Ther20081381087109019195335
   PubMed Web of Science ®Google Scholar
• AnanworanichJKosalaraksaPHillASiangphoeUBergshoeffAPancharoenCPharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pre-treated childrenPediatr Infect Dis J2005241087487916220084
   PubMed Web of Science ®Google Scholar
• KosalaraksaPBunupuradahTEngchanilCBoonrakPIntasanJLumbiganonPDouble boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pre-treated children at 48 weeksPediatr Infect Dis J200827762362818520443
   PubMed Web of Science ®Google Scholar
• BunupuradahTvan der LugtJKosalaraksaPEngchanilCBoonrakPPuthanakitTSafety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pre-treated children at 96 weeksAntivir Ther200914224124819430099
   PubMed Web of Science ®Google Scholar
• RobbinsBLCapparelliEVChadwickEGYogevRSerchuckLWorrellCPharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitorsAntimicrob Agents Chemother20085293276328318625762
   PubMed Web of Science ®Google Scholar